Reported Earlier, Lilly's EBGLYSS Wins FDA Approval For Every-Eight-Week Maintenance Dose In Moderate-To-Severe Atopic Dermatitis, Becoming Only Option With Six Annual Injections And No Required Topicals

뉴스 본문을 불러오고 있어요.

Reported Earlier, Lilly's EBGLYSS Wins FDA Approval For Every-Eight-Week Maintenance Dose In Moderate-To-Severe Atopic Dermatitis, Becoming Only Option With Six Annual Injections And No Required Topicals | 웨이프 WAPE

Reported Earlier, Lilly's EBGLYSS Wins FDA Approval For Every-Eight-Week Maintenance Dose In Moderate-To-Severe Atopic Dermatitis, Becoming Only Option With Six Annual Injections And No Required Topicals

기사 요약

관련 종목

댓글 —